Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 5: zenagamtide once weekly for overweight or obesity with knee osteoarthritis
2024-520444-42-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Modality
- Small Molecules, Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and knee osteoarthritis (OA) comparing Zenagamtide once weekly with Placebo once weekly (2 arms). Primary endpoints: Relative change in body weight and Change in WOMAC Osteoarthritis Index NRS 3.1 (24-hour) pain score. Planned start Apr 2026; status: authorised.
02
Drugs
amycretin
03
Conditions
obesityOverweightknee osteoarthritis (OA)
Beyond the preview
Go deeper on 2024-520444-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520444-42-00.